FAS abolished agreed prices for “Bartizar” medicinal drug

08-03-2017 | 08:40

The Federal Antimonopoly Service (FAS Russia) established that the drug manufacturer submitted false information on the prices of raw materials supplies and set an excessive euro exchange rate in its estimates

Registering prices for “Bartizar” medicinal drug (“Bortezomib” International Non-Proprietary Name) manufactured by “Sotex” “PhamFirma” CJSC (Russia) submitted an agreement with the raw materials supplier (“in-bulk”), where the price for the raw material is indicated at 106 euro. According to the customs freight declaration, the actual price for the import of raw materials was 48 euro at the time of price registering. Thus, the pharmaceutical company overrated the raw materials procurement price by 2.2 times.

Moreover, recalculating the contract price for the raw materials in RUB, the drug manufacturer set an excessive euro exchange course, which additionally aggravated the exposed fact of the submitted false information.

Based on Clause 25 of the Rules1, approved by No. 865 Decree of the Government of the Russian Federation of 29.11.2010, FAS abolished the earlier decisions on agreeing the ceiling ex-works manufacturer prices for “Bartizar” medicinal drug.

Head of FAS Department for Control over Social Sphere and Trade, Timophey Nizhegorodtsev commented: “We believe that it will be a clear signal to the companies that submitted unreliable data but hope to register and further maintain overrated prices”.

Reference:

1. Clause 25 of the Rules for state registration and re-registration of the ceiling ex-works prices set by medicinal drug manufacturers for the drugs included in the list of vital and essential medicinal drugs: “The Federal Antimonopoly Service abolishes a decision on agreeing the ceiling ex-works manufacturer price for a medicinal drug if after making such a decision it was established that the holder or owner of the registration certificate for the medicinal drug (a person authorized by them) presented unreliable data that influenced the result of the decision-making.

The Ministry of Healthcare of the Russian Federation abolishes a decision on state registration or re-registration of the ceiling ex-works manufacturer price for the drug if after making the decision it was established that the holder or owner of the registration certificate for the medicinal drug (a person authorized by them) presented unreliable data that affected the result of decision-making by the Ministry, as well as if the Federal Antimonopoly Service reversed a decision on agreeing the ceiling ex-works manufacturer price for the medicinal drug. In these cases the Ministry of Healthcare of the Russian Federation removes the registered (re-registered) ceiling ex-works price from the State Register”.



Site Map

News & Events Press Releases Media Releases Image Library About the FAS Russia What We Do General Information Mission, Goals, Values Priority Setting Institutional Memory Stakeholders Engagement Center for Education and Methodics Our History Our Structure Powers of Head and Deputy Heads Our Ratings GCR Using our website International Cooperation Treaties & Agreements International Working Groups Working Group on Research of Competition Issues in the Market of International Telecommunications (Roaming) Meetings Working Group for Studying Competition Problems in the Pharmaceutical Sector Concept Note Meetings OECD Competition Committee OECD meetings 2013 OECD meetings 2014 OECD meetings 2015 OECD meetings 2016 OECD meetings 2017 OECD meetings 2018 FAS Annual Reports OECD-GVH RCC RCC Newsletter ICAP Council on Advertising Headquarters for Joint Investigations UNCTAD 13th session IGE UNCTAD Resolution Russian contributions 14th session IGE UNCTAD Resolution Russian contributions 15th session IGE UNCTAD 16th session IGE UNCTAD 17th session IGE UNCTAD EEU Model Law on Competition ICN BRICS WG (Markets of Social Importance) EU APEC Competition Policy and Law Group Annual meetings Projects ERRA Full Members Organizational Structure Archive Working Group on Investigating Issues on Pricing in the Oil and Oil Product Markets and Methods of their Functioning Meetings Document Library Legislation Reports & Analytics Cases & decisions Contacts Give feedback Contact us Links Authorities Worldwide